Skip to main content

Nicolai Lagoni is a partner in the German Corporate Group with deep experience in the fields of M&A, joint ventures and corporate law. His clients are multinational corporations and investors, which he regularly advises on complex cross-border transactions.

Nicolai has wide-ranging experience in the areas of technology, real estate and pharmaceuticals & life sciences.

Prior to joining the firm, Nicolai worked for several years in the German Corporate/M&A Groups of Hengeler Mueller and Olswang. In 2009 he was seconded to an international pharmaceutical company.

Concentrations

  • Private & public M&A
  • Private equity
  • Joint ventures
  • Corporate law
  • Capital markets

取扱分野

受賞歴・所属団体

  • Listed, Chambers Global, "Corporate/M&A: Mid-Market - Germany," 2022-2024
  • Listed, Chambers Europe, "Corporate/M&A: Mid-Market - Germany," 2022-2024
  • Listed, EMEA Legal 500, "Corporate M&A - M&A" and "Private Equity - Transactions," 2024
  • Listed, IFLR1000, "Notable Practitioner," M&A, 2019-2024
  • JUVE Handbook 2018/2019: "frequently recommended" for corporate law: "creative person, thinks strategically", competitors describe him as "highly skilled and structured"
  • Recommended by Handelsblatt/Best Lawyers in Germany 2018/2019 for M&A
  • Team Member, Chambers USA Award for Excellence, Real Estate, 2017
  • Listed by The Legal 500 for M&A/Transactions
  • Listed by IFLR1000 for M&A in Pharmaceuticals in Life Sciences, Real Estate and Technology & telecommunications
  • Scholar of the International Max Planck Research School Maritime Affairs

学歴・資格・言語

学歴
  • Second Legal State Exam, Universität Hamburg/Germany
  • Dr. iur., Universität Hamburg, Germany/International Max Planck Research School Maritime Affairs, 2007
  • First Legal State Exam, Rheinische Friedrich-Wilhelms-Universität, Bonn/Germany
弁護士資格
  • Germany
言語
  • German
  • English
  • French

Related Capabilities

コーポレート Venture Capital & Emerging Technology M&A プライベート・エクイティ 不動産投資信託 (REIT) 不動産 Technology, Media & Telecommunications Life Sciences & Medical Technology